Both Ipamorelin and MK-677 are growth hormone secretagogues, meaning they stimulate the body's own production and release of growth hormone. Ipamorelin has been investigated for its role in accelerating gastrointestinal recovery, particularly in reducing postoperative ileus after bowel surgery, with studies indicating a reduction in recovery time and hospital stays. MK-677 has been explored for its potential in addressing age-related decline by restoring growth hormone and IGF-I levels in older adults, aiming to improve muscle mass and reduce frailty. Additionally, MK-677 has been studied in the context of Alzheimer's disease treatment and its effects on bone turnover in obese young men.
| Ipamorelin | MK-677 | |
|---|---|---|
| Drug class | ghrh secretagogue, ghrelin mimetic | n/a |
| Studies in corpus | 45 | 96 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 | case report · 4 rct · 10 other · 20 preclinical animal · 29 in vitro · 15 review · 15 |
| Studies with explicit sample size | 3 | 2 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Ipamorelin and MK-677 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1210 Ipamorelin batches across 562 manufacturers, 99.44% avg purity.
We tested 29 MK-677 batches across 24 manufacturers, 98.15% avg purity.
We hold deeper lab coverage on Ipamorelin (1210 batches tested). Ipamorelin edges ahead on average measured purity (99.44% vs 98.15%) — a narrow gap; weigh it against failed-batch and underdose counts above.
No direct head-to-head trials in our corpus. Indirect comparison only. Ipamorelin's research in our corpus primarily focuses on its application in accelerating bowel recovery post-surgery, with studies providing early evidence of its efficacy in reducing postoperative ileus. Its pharmacology, including the quantitative link between systemic exposure and growth hormone-releasing effects, has been mapped in healthy humans. MK-677, while also a growth hormone secretagogue, has a broader range of investigated applications in our indexed studies. These include its potential for improving body composition and function in older adults by restoring youthful growth hormone levels, its exploration as a treatment for Alzheimer's disease, and its observed effects on boosting bone turnover in obese young men. While both peptides act as growth hormone secretagogues, the specific therapeutic areas explored in the available research differ, with Ipamorelin showing promise in GI motility and MK-677 being investigated for age-related decline, neurological conditions, and bone metabolism.
Looking for vendor-level purity, endotoxin, and HPLC data on Ipamorelin or MK-677? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.